Zika Virus (ZIKV) is transmitted primarily by Aedes aegypti mosquitoes, resulting in asymptomatic infection, or acute illness with a fever and headache, or neurological complications, such as Guillain-Barre syndrome or fetal microcephaly. Previously, we determined that AgBR1, a mosquito salivary protein, induces inflammatory responses at the bite site, and that passive immunization with AgBR1 antiserum influences mosquito-transmitted ZIKV infection. Here, we show that the active immunization of mice with AgBR1 adjuvanted with aluminum hydroxide delays lethal mosquito-borne ZIKV infection, suggesting that AgBR1 may be used as part of a vaccine to combat ZIKV.
CITATION STYLE
Wang, Y., Marin-Lopez, A., Jiang, J., Ledizet, M., & Fikrig, E. (2020). Vaccination with aedes aegypti agbr1 delays lethal mosquito-borne zika virus infection in mice. Vaccines, 8(2). https://doi.org/10.3390/vaccines8020145
Mendeley helps you to discover research relevant for your work.